Newsroom

Press Releases

Sorry, I don't understand. Please try again

Immunology

Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)

December 2, 2024
United States

Read more
Immunology

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

November 22, 2024
United States

Read more
Oncology

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting

November 19, 2024
United States

Read more
Immunology

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

November 18, 2024
United States

Read more
Oncology

CHMP recommends RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

November 15, 2024
Belgium

Read more
Immunology

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren’s disease study

November 14, 2024
United States

Read more
Immunology

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren’s disease

November 11, 2024
United States

Read more
Oncology

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma

November 8, 2024
United States

Read more
Immunology

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

November 7, 2024
United States

Read more
Communicable diseases & vaccines

European Commission Approves Expanded Use of HIV-1 Therapy
EDURANT® (rilpivirine) in Younger Pediatric Patients

October 28, 2024
Belgium

Read more

Search Results

No Results

Recently Viewed

Newsroom

Press Releases